BioSpace News Archive

DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced the pricing of its upsized underwritten public offering of 8,219,178 shares of its common stock at a public offering price of $36.50 per share.

Collaboration brings together Avectas’ breakthrough cell engineering technology and Inceptor Bio’s CAR-T platform

Mapi Pharma Ltd. announced today it will host a key opinion leader webinar on Glatiramer Acetate (GA) Depot, a potential long-acting injection solution for multiple sclerosis (MS) patients, on Wednesday, October 19, 2022 at 10:30 AM Eastern Time.

Tevogen Bio®, is a late-stage clinical biotechnology company specializing in the development of cellular immunotherapies in virology, neurology, and oncology.

NeuroLogica Corp., a subsidiary of Samsung Electronics Co. Ltd., announced today that its state-of-the-art Elite Mobile Computed Tomography (CT) systems have received the European Union (EU) CE marking via compliance with the new EU Medical Device Regulation (MDR 2017/745).

AlloSource®, one of the largest allograft providers in the U.S., today announced it was awarded a multi-year contract by the Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR) in the Department of Health and Human Services (HHS).

A research announcement to leverage the unique microgravity environment of the International Space Station for in-space production applications within the biomedical community is now open.